491 related articles for article (PubMed ID: 17378599)
1. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
2. Development of albumin-binding camptothecin prodrugs using a Peptide positional scanning library.
Schmid B; Warnecke A; Fichtner I; Jung M; Kratz F
Bioconjug Chem; 2007; 18(6):1786-99. PubMed ID: 17915955
[TBL] [Abstract][Full Text] [Related]
3. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen.
Kratz F; Mansour A; Soltau J; Warnecke A; Fichtner I; Unger C; Drevs J
Arch Pharm (Weinheim); 2005 Oct; 338(10):462-72. PubMed ID: 16211657
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.
Warnecke A; Fichtner I; Sass G; Kratz F
Arch Pharm (Weinheim); 2007 Aug; 340(8):389-95. PubMed ID: 17628030
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).
Graeser R; Chung DE; Esser N; Moor S; Schächtele C; Unger C; Kratz F
Int J Cancer; 2008 Mar; 122(5):1145-54. PubMed ID: 17973264
[TBL] [Abstract][Full Text] [Related]
6. Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA).
Chung DE; Kratz F
Bioorg Med Chem Lett; 2006 Oct; 16(19):5157-63. PubMed ID: 16875815
[TBL] [Abstract][Full Text] [Related]
7. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2.
Mansour AM; Drevs J; Esser N; Hamada FM; Badary OA; Unger C; Fichtner I; Kratz F
Cancer Res; 2003 Jul; 63(14):4062-6. PubMed ID: 12874007
[TBL] [Abstract][Full Text] [Related]
8. Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: synthesis and antitumor efficacy.
Warnecke A; Kratz F
Bioconjug Chem; 2003; 14(2):377-87. PubMed ID: 12643748
[TBL] [Abstract][Full Text] [Related]
9. In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP).
Elsadek B; Graeser R; Esser N; Schäfer-Obodozie C; Tsurumi C; Abu Ajaj K; Warnecke A; Unger C; Saleem T; Kratz F
Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):14-21. PubMed ID: 21042336
[TBL] [Abstract][Full Text] [Related]
10. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.
Kratz F; Warnecke A; Scheuermann K; Stockmar C; Schwab J; Lazar P; Drückes P; Esser N; Drevs J; Rognan D; Bissantz C; Hinderling C; Folkers G; Fichtner I; Unger C
J Med Chem; 2002 Dec; 45(25):5523-33. PubMed ID: 12459020
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B.
Abu Ajaj K; Graeser R; Fichtner I; Kratz F
Cancer Chemother Pharmacol; 2009 Jul; 64(2):413-8. PubMed ID: 19229536
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study.
Elsadek B; Graeser R; Esser N; Schäfer-Obodozie C; Abu Ajaj K; Unger C; Warnecke A; Saleem T; El-Melegy N; Madkor H; Kratz F
Eur J Cancer; 2010 Dec; 46(18):3434-44. PubMed ID: 20933385
[TBL] [Abstract][Full Text] [Related]
13. Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs.
Conover CD; Greenwald RB; Pendri A; Shum KL
Anticancer Drug Des; 1999 Dec; 14(6):499-506. PubMed ID: 10834271
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, characterization, and preliminary in vivo tests of new poly(ethylene glycol) conjugates of the antitumor agent 10-amino-7-ethylcamptothecin.
Guiotto A; Canevari M; Orsolini P; Lavanchy O; Deuschel C; Kaneda N; Kurita A; Matsuzaki T; Yaegashi T; Sawada S; Veronese FM
J Med Chem; 2004 Feb; 47(5):1280-9. PubMed ID: 14971908
[TBL] [Abstract][Full Text] [Related]
15. Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis: an experimental study.
Shao LH; Liu SP; Hou JX; Zhang YH; Peng CW; Zhong YJ; Liu X; Liu XL; Hong YP; Firestone RA; Li Y
Cancer; 2012 Jun; 118(11):2986-96. PubMed ID: 22006342
[TBL] [Abstract][Full Text] [Related]
16. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
Abu Ajaj K; Graeser R; Kratz F
Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
[TBL] [Abstract][Full Text] [Related]
17. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
[TBL] [Abstract][Full Text] [Related]
18. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
[TBL] [Abstract][Full Text] [Related]
19. The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH.
Flowers JL; Hoffman RM; Driscoll TA; Wall ME; Wani MC; Manikumar G; Friedman HS; Dewhirst M; Colvin OM; Adams DJ
Cancer Chemother Pharmacol; 2003 Sep; 52(3):253-61. PubMed ID: 12783198
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] that targets integrin alphavbeta3.
Ryppa C; Mann-Steinberg H; Fichtner I; Weber H; Satchi-Fainaro R; Biniossek ML; Kratz F
Bioconjug Chem; 2008 Jul; 19(7):1414-22. PubMed ID: 18578486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
